Perspective Therapeutics, Inc.CATXEarnings & Financial Report
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.
Revenue
$2.9M
Gross Profit
$1.4M
Operating Profit
$-1.4M
Net Profit
$-1.3M
Gross Margin
49.5%
Operating Margin
-47.3%
Net Margin
-46.3%
YoY Growth
11.9%
EPS
$-0.01
Perspective Therapeutics, Inc. Q1 FY2022 Financial Summary
Perspective Therapeutics, Inc. reported revenue of $2.9M (up 11.9% YoY) for Q1 FY2022, with a net profit of $-1.3M (down 80.8% YoY) (-46.3% margin). Cost of goods sold was $1.5M, operating expenses totaled $2.8M.
Key Financial Metrics
| Total Revenue | $2.9M |
|---|---|
| Net Profit | $-1.3M |
| Gross Margin | 49.5% |
| Operating Margin | -47.3% |
| Report Period | Q1 FY2022 |
Perspective Therapeutics, Inc. Quarterly Revenue & Net Profit History
Perspective Therapeutics, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2023 | $-3.8M | — | N/A | N/A |
| Q3 FY2022 | $1.7M | -33.0% | $-4.1M | -236.9% |
| Q1 FY2022 | $2.9M | +11.9% | $-1.3M | -46.3% |
Income Statement
| Q1 2022 | Q3 2022 | Q4 2023 | |
|---|---|---|---|
| Revenue | $2.9M | $1.7M | $-3.8M |
| YoY Growth | 11.9% | -33.0% | N/A |
Balance Sheet
| Q1 2022 | Q3 2022 | Q4 2023 | |
|---|---|---|---|
| Assets | $66.1M | $62.5M | $97.9M |
| Liabilities | $2.9M | $4.8M | $22.7M |
| Equity | $63.2M | $57.7M | $75.2M |
Cash Flow
| Q1 2022 | Q3 2022 | Q4 2023 | |
|---|---|---|---|
| Operating CF | $-1.4M | $-1.8M | $-9.0M |